Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan for Occult Cardiovascular Disease in Secondhand Smoke Exposure
NCT04715568Phase 4Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Mar 2021
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of losartan in cardiovascular disease (CVD) and hypertension (HTN) (2 arms), sponsored by University of California, San Francisco. Primary endpoints: Left Ventricular Ejection Fraction, Aortic pulse wave velocity and 2 more. Started Mar 2021; status: recruiting.
02
Drugs
losartan
03
Conditions
cardiovascular disease (CVD)hypertension (HTN)
Beyond the preview
Go deeper on NCT04715568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04715568.